drugset / Trial / NCT06255665
A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-79032421 and to determine the safety and tolerability of JNJ-79032421 at the RP2D(s).
Timeline
- Start
- 2024-02-09
- Primary completion
- 2025-06-23
- Completion
- 2025-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-79032421 | Unknown | — | — |
Indications
No indication recorded.